STING-mediated tumor microenvironment remodeling: turning adaptive resistance into therapeutic vulnerability.

Resistance to cancer immunotherapy is frequently sustained by immune exclusion, suppressive myeloid and stromal programs, abnormal tumor vasculature, and inhibitory checkpoint-ligand expression within the tumor microenvironment. Activation of the cGAS-STING (cyclic GMP-AMP Synthase)- (Stimulator of Interferon Genes) pathway has emerged as a context-dependent strategy to modulate the cancer immunity cycle and remodel resistant tumor ecosystems, with the potential to convert selected poorly inflamed immune-excluded tumors into immune-reactive lesions. However, STING activation does not simply "turn on" antitumor immunity. By reprogramming the tumor microenvironment, it can generate both therapeutic opportunity and compensatory resistance, including the induction of PD-L1 and PD-L2 on tumor, immune cells, stroma, and endothelial compartments. Recent evidence suggests that this adaptive response may be therapeutically exploited rather than merely counteracted. STING-driven remodeling may sensitize non-malignant tumor microenvironment compartments, including endothelial and myeloid cells, to Fc-engineered antibodies targeting PD-L1 and PD-L2. This Perspective discusses STING agonism as a broad immuno-oncology priming strategy and reframes inducible PD-L1/PD-L2 expression from an adaptive escape mechanism to an emergent transient, spatially organized, and therapeutically actionable cancer selective target. We propose that rational combinations of STING agonists with Fc-engineered PD-L1/PD-L2-targeting antibodies, guided by dynamic and spatial biomarkers, could overcome resistance to conventional immune checkpoint blockade in tumors with minimal T-cell infiltration but targetable tumor vasculature. Emerging delivery platforms, including antibody-conjugated STING agonists, may further improve the therapeutic index of this approach by concentrating innate immune activation within antigen-defined tumor niches and reducing off-tumor inflammatory activation.